NCT07190690

Comparison of a Contemporary Sirolimus-eluting Stent (ihtDEStiny®) With Another Everolimus-eluting Stent (Xience™), Both With Permanent Polymers, in Patients With Acute Coronary Syndrome and de Novo Coronary Artery Lesions

Comparison of a Contemporary Sirolimus-eluting Stent (ihtDEStiny®) With Another Everolimus-eluting Stent (Xience™), Both With Permanent Polymers, in Patients With Acute Coronary Syndrome and de Novo Coronary Artery Lesions (DestinACSion Study)

• Status: Recruiting
• Phase: N/A
• Study type: Interventional
• Enrollment: 2,100 (estimated)
• Sponsor: Fundación EPIC · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

To evaluate the efficacy of the two DES (Drug Eluting Stent) used in terms of device-related adverse events at 12 months after PCI (Percutaneous Coronary Intervention). To compare the clinical safety and efficacy by comparing net clinical events (defined as the combination of ischemic and hemorrhagic events) of the two DES used at 12 months after PCI.

Detailed description

To evaluate the efficacy of the two DES (Drug Eluting Stent) used in terms of device-related adverse events at 12 months after PCI (Percutaneous Coronary Intervention). To compare the clinical safety and efficacy by comparing net clinical events (defined as the combination of ischemic and hemorrhagic events) of the two DES used at 12 months after PCI.

Conditions

• Coronary Artery Disease

Interventions

Type	Name	Description
DEVICE	ihtDEStiny® DES implanted	ihtDEStiny® DES implanted
DEVICE	Xience™ DES implanted	Xience™ DES implanted

Timeline

• Start date: 2025-12-19
• Primary completion: 2029-10-15
• Completion: 2030-10-15
• First posted: 2025-09-24
• Last updated: 2026-04-13

Locations

13 sites across 1 country: Spain